Loading stock data…
Maravai LifeSciences Holdings (MRVI)
$6.39+0.17 (+2.73%)
After Hours$6.43+0.04 (+0.63%)· Last close Jun 29
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maravai LifeSciences Holdings, Inc. in the Healthcare sector is trading at $6.39 with a market capitalization of $1.9B. Wall Street consensus targets $5.70 (5 analysts), implying a -10.8% move over the next 12 months. The stock is currently near its 52-week high of $6.55, remaining 77.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -10.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $65.84M↑ | $49.87M↑ | $41.63M↓ | $47.40M↑ | $46.85M |
| Gross Profit | $33.70M↑ | $12.84M↑ | $5.66M↓ | $7.77M↑ | $7.72M |
| Operating Income | $720,000↑ | -$22.53M↑ | -$33.59M↑ | -$35.69M↑ | -$36.73M |
| Net Income | -$3.73M↑ | -$35.68M↓ | -$25.56M↑ | -$39.59M↓ | -$29.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.42%
Volume
Today's trading volume
3.06M
Recent News
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 7, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) affirmed a strong start to the year, driven by strong demand in the core TriLink base business and strength in the higher-margin portfolio. Increased focus on cost structure and […]
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance
Price target work on Maravai LifeSciences Holdings has shifted, with updated modeling lifting the estimated fair value per share from US$4.33 to US$5.70. Analysts are tying this move to refreshed assumptions that reflect recent Q4 results and new guidance, while still showing a split between more bullish and more cautious views on the stock. As you read on, you will see how these changing targets fit into the broader story and how to track the evolving analyst narrative over time. Analyst...
Maravai (MRVI) Q1 2026 Earnings Transcript
As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update and our CFO, Rajesh Asarpota, will review our financial results. At Cygnus, revenue grew a little more than 1% year over year.
Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary
Moby summary of Maravai LifeSciences Holdings, Inc.'s Q1 2026 earnings call
Maravai LifeSciences Q1 Earnings Call Highlights
Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year. On the company’s earnings call, CEO